

March 15, 2021

Notice on adoption as the Next Generation Innovation Creation Project 2020

We are pleased to announce that our project on the development of basic technology for the next generation High Intensity Focused Ultrasound therapy system has been selected as one of the projects to be supported by the Tokyo Metropolitan Government and the Tokyo Metropolitan Small and Medium Enterprise Support Center under the 2020 Next Generation Innovation Creation Project grant program. With the adoption of this project, we will further accelerate the development of the next-generation HIFU treatment device, an ultra-minimally invasive cancer treatment device, and work to bring a new future to cancer patients as soon as possible.

[SONIRE Therapeutics Inc. (hereinafter, "SONIRE")]

SONIRE is a company that develops High Intensity Focused Ultrasound (HIFU) therapy systems by utilizing the technology and know-how built up at Tokyo Women's Medical University, Tohoku University, and Tokyo Medical University. SONIRE's vision is to bring a new future to cancer patients through acoustic engineering (ultrasound). The company is promoting development to treat pancreatic cancer which is an especially intractable cancer.

For more information, please visit <https://www.sonire-therapeutics.com>